Premium
Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes
Author(s) -
GarciaManero Guillermo,
DiezCampelo Maria,
Vellenga Edo,
Jacoby Meagan A.,
Merchan Brayan,
Breems Dimitri,
Cortelezzi Agostino,
Doronin Vadim,
Gomez Valle,
Beckers Marielle,
Della Porta Matteo Giovanni,
Varsos Helen,
Xiu Liang,
DeAngelis Nikki,
Nnane Ivo,
Rose Esther,
Eygen Koen
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26095
Subject(s) - daratumumab , medicine , myelodysplastic syndromes , multiple myeloma , bone marrow , immunology , myeloid leukemia , oncology , myeloid , bortezomib